Drug Eruptions: A Challenge for Dermatologists and First Contact Physicians
Main Article Content
Abstract
Adverse drug reactions are quite frequent in current medical practice, being the skin manifestations the most commonly observed, and although they generally have a benign and self-limiting evolution, but in exceptional cases they can be serious and even fatal. The priority in the evaluation of toxicoderma is established in the identification and distinction of severe skin adverse reactions, the so-called SCAR, among which include Stevens Johnson syndrome (SJS), toxic epidermal necrolysis (TEN) and drug-induced hypersensitivity syndrome/drug reaction with the presence of eosinophilia and systemic symptoms (DISH-DRESS), to which should be added acute generalized exanthematous pustulosis (AGEP). Unfortunately, however, our current knowledge does not allow us to determine the true incidence of these reactions, to establish the diagnosis and its causal relationship with certainty, or even to be able to anticipate its appearance.
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
References
I. Fernández Herrera JR, L. Erupciones cutáneas medicamentosas. Barcelona: Signament Edicions; 2003.
II. Chung WH, Wang CW, Dao RL. Severe cutaneous adverse drug reactions. J Dermatol. 2016;43(7):758-66.
III. Kanaan AO, Donovan JL, Duchin NP, Field TS, Tjia J, Cutrona SL, et al. Adverse drug events after hospital discharge in older adults: types, severity, and involvement of beers criteria medications. J Am Geriatr Soc. 2013;61(11):1894-9.
IV. Roujeau JC, Stern RS. Severe adverse cutaneous reactions to drugs. N Engl J Med. 1994;331(19):1272-85
V. Darlenski R, Kazandjieva J, Tsankov N. Systemic drug reactions with skin involvement: Stevens-Johnson syndrome, toxic epidermal necrolysis, and DRESS. Clin Dermatol. 2015;33(5):538-41.
VI. Stander S, Metze D, Luger T, Schwarz T. [Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS): a review]. Hautarzt. 2013;64(8): 611-22; quiz 23-4.
VII. Criado PR, Criado RF, Avancini JM, Santi CG. Drug reaction with Eosinophilia and Systemic Symptoms (DRESS)/Drug-induced Hypersensitivity Syndrome (DIHS): a review of current concepts. An Bras Dermatol. 2012;87(3):435-49.
VIII. Inomata N. Recent advances in drug-induced angioedema. Allergol Int. 2012;61(4):545-57.
IX. Simons FE, Ardusso LR, Dimov V, Ebisawa M, El-Gamal YM, Lockey RF, et al. World Allergy Organization Anaphylaxis Guidelines: 2013 update of the evidence base. Int Arch Allergy Immunol. 2013;162(3):193-204.
X. Halevy S, Shai A. Lichenoid drug eruptions. J Am Acad Dermatol. 1993; 29(2Pt1):249-55.
XI. Thompson DF, Skaehill PA. Drug-induced lichen planus. Pharmacotherapy. 1994;14(5):561-71.
XII. Schneider JA, Cohen PR. Stevens-Johnson Syndrome and Toxic epidermal necrolysis: a concise review with a comprehensive summary of therapeutic interventions emphasizing supportive measures. Adv Ther. 2017;34(6):1235-44.
XIII. Schwartz RA, McDonough PH, Lee BW. Toxic epidermal necrolysis: Part II. Prognosis, sequelae, diagnosis, differential diagnosis, prevention, and treatment. J Am Acad Dermatol. 2013;69(2):187,e1-16; quiz 203-4.
XIV. Huang YC, Chien YN, Chen YT, Li YC, Chen TJ. Intravenous immunoglobulin for the treatment of toxic epidermal necrolysis: a systematic review and meta-analysis. G Ital Dermatol Venereol. 2016;151(5):515-24.
XV. Flowers H, Brodell R, Brents M, Wyatt JP. Fixed drug eruptions: presentation, diagnosis, and management. South Med J. 2014;107(11):724-7.
XVI. 16. Andrade P, Brinca A, Goncalo M. Patch testing in fixed drug eruptions-a 20-year review. Contact Dermatitis. 2011;65(4):195-201.
XVII. Degen A, Alter M, Schenck F, Satzger I, Völker B, Kapp A, et al. The hand-foot-syndrome associated with medical tumor therapy - classification and management. J Dtsch Dermatol Ges. 2010;8(9):652-61.
XVIII. Stavropoulos PG, Soura E, Antoniou C. Drug-induced pemphigoid: a review of the literature. J Eur Acad Dermatol Venereol. 2014;28(9):113340.
XIX. Ferreira J, Toda-Brito H, Moura MC, Sachse MF, Costa-Rosa J. BRAFiassociated panniculitis - an emerging side effect with a variable histological picture: report of two cases and review of the literature. J Cutan Pathol. 2017;44(3):307-9.
XX. 20. Guhl G, Díaz-Ley B, García-García C, Fraga J, García-Díez A. Chemotherapy-induced subacute lupus erythematosus. Lupus. 2009;18(9): 859-60.
XXI. Rubin RL. Drug-induced lupus. Expert Opin Drug Saf. 2015;14(3):36178.
XXII. Grau RG. Drug-induced vasculitis: new insights and a changing lineup of suspects. Curr Rheumatol Rep. 2015;17(12):71.
XXIII. Guhl G, González-de Arriba A, Dauden E. [Epidermal growth factor receptor inhibitors side effects]. Actas Dermosifiliogr. 2006;97(5):296-310.
XXIV. Szatkowski J, Schwartz RA. Acute generalized exanthematous pustulosis (AGEP): A review and update. J Am Acad Dermatol. 2015;73(5):843-8.
XXV. Robert C, Sibaud V, Mateus C, Verschoore M, Charles C, Lanoy E, et al. Nail toxicities induced by systemic anticancer treatments. Lancet Oncol. 2015;16(4):e181-9.
XXVI. Kyonen M, Folatre I, Lagos X, Vargas S. [Comparison of two methods to assess causality of adverse drug reactions]. Rev Med Chil. 2015;143(7): 880-6.
XXVII. Rerkpattanapipat T, Chiriac AM, Demoly P. Drug provocation tests in hypersensitivity drug reactions. Curr Opin Allergy Clin Immunol. 2011; 11(4):299-304.
XXVIII. Fernández Figueras MT PL. Toxicodermias. Piel. 2001;12(2): 74-80